China's Clover generates US$230m in funding as its COVID-19 vaccine candidate edges towards late stage clinical trial
Clover Biopharmaceuticals | Science | Trimer-Tag™
Clover, GSK collaborate on Coronavirus vaccine candidate S-Trimer
Clover Biopharmaceuticals | Home
Clover Biopharmaceuticals starts construction of new R&D center in Shanghai
CEPI expands partnership with Clover Biopharmaceuticals to rapidly advance development and manufacture of COVID-19 vaccine candidate – CEPI
Clover Biopharmaceuticals Biomanufacturing Facility, Changxing, China
Clover Biopharmaceuticals starts Phase I Covid-19 vaccine trial
Clover Biopharmaceuticals Becomes the 9th Enterprise in CDHT Listed on the Hong Kong Stock Exchange_News_GaoxinEnglish
Magnetic and trimer order parameters. a "Clover-leaf" structural domain... | Download Scientific Diagram
Clover and Dynavax to begin Covid-19 vaccine candidate efficacy trial
Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
Using GSK and Dynavax tech, Clover kick-starts COVID-19 vax trial with data drop in August | Fierce Biotech
Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
Clover Biopharmaceuticals Announces Publication of Phase 1 Clinical Trial Data for its Adjuvanted COVID-19 Vaccine Candidates in The Lancet
COVID-19 S-Trimer vaccine candidates show promise in early trials
PharmaBoardroom - China's Clover Biopharmaceuticals Partners with GSK on COVID-19 Vaccine
Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System - Clover Biopharmaceuticals
Clover and Dynavax initiate dosing in Covid-19 vaccine candidate trial
Chinese COVID vaccine maker Clover Biopharma set for HKEX debut - Nikkei Asia
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications
GSK gives Clover adjuvant for vaccine against 'indispensable' COVID-19 protein | Fierce Biotech
GSK recruits Clover Biopharmaceuticals in latest coronavirus effort - PharmaTimes
CEPI extends partnership with Clover to fund COVID-19 vaccine candidate through global Phase 2/3 study to licensure – CEPI
Clover Biopharmaceuticals on Twitter: "We are partnering with @AscentagePharma to explore innovative combination therapy approaches in oncology. Our collaboration will evaluate Clover's SCB-313 with Ascentage Pharma's APG-1387 in a Phase 1b/2 clinical
Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate
